Aurinia Pharmaceuticals Inc (AUPH)

[cervelo]

ok let me see if i get this right. we beat the street only because the share price dropped reducing derivative warrant liability. so if the share price increases next quarter the loss will be greater. administration cost rose 400,000 a month and phase 3 is just beginning. research costs tripled over a year ago. plan to have all phase 3 patients in 18 months. minimum 12 more months for trial and then data. from a business point of view and accelerating cash burn rates we will run out of money. And what could be a positive still no mention of agreement and cash for dog dry eye deal.

if someone understands accounting better than I show me a positive.
I hope I am wrong but friday could bring a minimum 5% drop in share price.
if you like short term losses we are in the right place.

management awarded themselves $718,000 2nd quarter in stock yet they failed to say at what price.
managment seems to be filling their own pockets at the expense on shareholders.

for a company with no current revenues they seem to have no problems with high payrolls.